# NRx Pharmaceuticals, Inc. (NRXP)

> Source: Nexqual · https://nexqual.com/NRXP · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, NRx Pharmaceuticals, Inc. (NRXP), nexqual.com/NRXP" · informational, not investment advice.

**Price:** USD 2.71 (+4.63% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 2.59 · day 2.48–2.77 · 52w 1.62–5.06 · market cap $117M · NCM

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $3.4M, net income -$23.5M (-691.8% margin) (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 38.5 (range 10–50).
- Total return with dividends: 1Y -10.9% vs S&P 500 +18.1%; 5Y -97.4% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.15, revenue estimate $1.3M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2024 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0K | $0K | $1.2M | $3.4M |
| Gross profit | — | — | — | $0K | $720K | — |
| Operating income | -$116M | -$44.3M | -$27.8M | -$18.5M | -$16.2M | -$19.9M |
| Net income | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M | -$23.5M |
| EPS (diluted) | -$19.80 | -$6.00 | — | — | — | — |
| Free cash flow | -$37.7M | -$39.8M | -$21.7M | -$10.6M | — | — |
| Gross margin | — | — | — | — | 58.8% | — |
| Operating margin | — | — | — | — | -1324.4% | -586.2% |
| Net margin | — | — | — | — | -2336.5% | -691.8% |
| Cash + short-term investments | $27.6M | $20.1M | $4.6M | $1.4M | $7.8M | — |
| Total debt | — | $10.5M | $18.3M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 34.6x · Earnings yield -20.01%

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 38.5 (low 10, high 50).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-01 | Ascendiant Capital | Target raised | Buy | $49 → $50 |
| 2026-09-14 | BTIG | Reiterated | Buy | $10 |
| 2026-08-25 | HC Wainwright & Co. | Reiterated | Buy | $45 |
| 2026-08-18 | BTIG | Reiterated | Buy | $10 |
| 2026-08-07 | BTIG | Target lowered | Buy | $25 → $10 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -10.9% | -97.4% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -10.9% | -51.6% |
| Volatility (annualized) | 82.6% | 111.2% |
| Max drawdown | -49.2% (Oct 2025→Feb 2026) | -98.8% (Oct 2021→Nov 2024) |

## Peers (Biotechnology)
DNTH (Dianthus Therapeutics, Inc.) USD 74.53 -3.93% · DFTX (Definium Therapeutics, Inc.) USD 34.26 -0.35% · MANE (Veradermics, Incorporated) USD 115.07 -1.02% · ORKA (Oruka Therapeutics, Inc.) USD 73.87 -5.53% · SRRK (Scholar Rock Holding Corporatio) USD 40.64 +0.30% · TVTX (Travere Therapeutics, Inc.) USD 52.79 +1.91%

## More
Full page: https://nexqual.com/NRXP · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt